AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06574412
Drug: cardonilizumab combined with renvastinib
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \&lt;60kg, 8mg, once a day, orally, for 4 cycles Weight \&gt;60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \&lt;60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \&gt; 60kg, 12mg, once a day, orally, a total of 8 cycles.
Trial: NCT04577027
Drug: Topical travoprost 0.004% solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
Trial: NCT05042687
Drug: Tc99m sestamibi
RxNorm normalized name: TECHNETIUM TC-99M SESTAMIBI 1 mg in 10 mL INTRAVENOUS INJECTION [Kit for the Preparation of Technetium Tc99m Sestamibi]
DrugBank: Technetium Tc-99m sestamibi (DB09161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06512389
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg taken morning and evening
Trial: NCT06195267
Drug: Sivelestat
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
Trial: NCT05824975
Drug: GI-102 subcutaneous (SC)
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
Trial: NCT05824975
Drug: GI-102
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Trial: NCT05824975
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
Trial: NCT05824975
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
Trial: NCT05824975
Drug: eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
Trial: NCT05824975
Drug: trastuzumab deruxtecan (T-DXd)
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
Trial: NCT05824975
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
Trial: NCT05824975
Drug: GI-102
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Trial: NCT03904498
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 100 mg tablets
Trial: NCT06220721
Drug: Nifedipine ER
RxNorm normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.
Trial: NCT05986136
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
Trial: NCT05986136
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
Trial: NCT06553547
Drug: Tenapanor
RxNorm normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenapanor 5 mg/mL solution
Trial: NCT04457076
Drug: LevoCept
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel-Releasing Intrauterine System
Trial: NCT06120166
Drug: Metabolically Armed CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
Trial: NCT05398484
Drug: Psilocybin 25 mgs
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
Trial: NCT05398484
Drug: Niacin 100mg
RxNorm normalized name: NIACIN 100MG TAB
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
Trial: NCT05957211
Drug: 0.09% cyclosporine A ophthalmic solution
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
Trial: NCT06329141
Drug: Vutiglabridin
RxNorm normalized name: Vutiglabridin
DrugBank: Vutiglabridin (DB18781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT06309745
Drug: Carboplatin AUC10
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC10
Trial: NCT05509595
Drug: Burosumab
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
Trial: NCT04410042
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05786573
Drug: Obexelimab
RxNorm normalized name: Obexelimab
DrugBank: Obexelimab (DB15032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
Trial: NCT06022003
Drug: AzaCITIDine Oral Tablet
RxNorm normalized name: azacitidine Oral Tablet
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AML study treatment
Trial: NCT06022003
Drug: Xospata
RxNorm normalized name: Xospata
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: R/R FLT3-mutated AML standard treatment
Trial: NCT06257576
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
Trial: NCT06069778
Drug: BNT321 Dose Level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06069778
Drug: BNT321 Dose Level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06543940
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vancomycin dose is 7.5 to 10 mg/kg
Trial: NCT05097716
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 200 mg provided as four 50 mg oral capsules
Trial: NCT05097716
Drug: Tolbutamide
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolbutamide 500 mg provided as one 500 mg oral tablet
Trial: NCT06304324
Drug: 0.9% Sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Trial: NCT06304324
Drug: 0.1mg/kg Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Trial: NCT06304324
Drug: 0.05ug/kg Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
Trial: NCT06288191
Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Trial: NCT05302921
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.
Trial: NCT05302921
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.
Trial: NCT04704999
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
Trial: NCT04704999
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
Trial: NCT05782270
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dual antiplatelet therapy combined with warfarin
Trial: NCT05782270
Drug: DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
Trial: NCT05579366
Drug: Rina-S
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Rina-S
Trial: NCT05579366
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin intravenous infusion
Trial: NCT05579366
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab intravenous infusion
Trial: NCT05579366
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab intravenous infusion
Trial: NCT05402332
Drug: AVTX-801
DrugBank: VTX-801 (DB17646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
Trial: NCT05858944
Drug: Intensive Home BP control
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
Trial: NCT05588648
Drug: Vactosertib
RxNorm normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
Trial: NCT05547750
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
Trial: NCT04781322
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
Trial: NCT04956432
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 300mg, tablets, QD
Trial: NCT05901519
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
Trial: NCT06163430
Drug: TERN-701
RxNorm normalized name: TERN-101
DrugBank: TERN-101 (DB16045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TERN-701 orally QD
Trial: NCT06550141
Drug: Emapalumab
RxNorm normalized name: Emapalumab
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An interferon gamma (IFNγ) blocking antibody
Trial: NCT06550141
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purine antagonist antimetabolite
Trial: NCT06550141
Drug: Axicabtagene Ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous treatment
Trial: NCT05053867
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled
Trial: NCT06102746
Drug: Sintilimab，Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
Trial: NCT00207974
Drug: Marine active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04221412
Drug: JNJ-53718678
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 will be administered as directed by treating physician.
Trial: NCT04973020
Drug: SHR6390、efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SHR6390 tablet single dose；Efavirenz single dose.
Trial: NCT05821517
Drug: Administration of METHOXYFLURANE
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
Trial: NCT05292950
Drug: ARO-MUC5AC
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
Trial: NCT06095128
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV infusions
Trial: NCT06095128
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib Tablets
Trial: NCT04456517
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablet
Trial: NCT05408065
Drug: Triamcinolone Hexacetonide and hyaluronic acid
RxNorm normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infiltration under fluoroscopy
Trial: NCT05408065
Drug: Triamcinolone Hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infiltration under fluoroscopy
Trial: NCT06575036
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
Trial: NCT06308913
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
Trial: NCT06210776
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT01093274
Drug: Sodium Picosulphate
RxNorm normalized name: Sodium Picosulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Sachets
Trial: NCT06332638
Drug: Tegoprazan 12.5mg
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
Trial: NCT06332638
Drug: Tegoprazan 25mg
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
Trial: NCT06332638
Drug: Famotidine 20mg
RxNorm normalized name: FAMOTIDINE 20MG TAB
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.